Biopharma leaders react to the forced resignation of CDER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; ...
Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has ...
Louisville Public Media on MSN6h
Eli Lilly's Alzheimer's drug not recommended by top European regulatorEli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...
Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say ...
MedPage Today on MSN1d
Sleep and Alzheimer's; Daylight Saving Time Evidence; Woman Who Smells Parkinson'sSleep deficiency was associated with atrophy of the inferior parietal region, which is observed in early Alzheimer's disease.
After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...
A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...
Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...
Kisunla (donanemab) would clearly not be an appropriate medicine for this type of access, given that it requires administration in an infusion clinic and close monitoring of patients to look for ...
The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...
A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...
Por THE ASSOCIATED PRESSUna comisión reguladora europea rechazó el tratamiento de Eli Lilly contra la enfermedad de Alzheimer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback